CT041
- Generic Name
- CT041
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
CT041 is an autologous CAR T-cell product candidate against protein Claudin18.2 (CLDN18.2).
- Associated Conditions
- -
- Associated Therapies
- -
Claudin18.2 CAR-T (CT041) in Patients with Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers
Phase 1
Active, not recruiting
- Conditions
- Gastric CancerPancreatic Cancer
- Interventions
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- CARsgen Therapeutics Co., Ltd.
- Target Recruit Count
- 110
- Registration Number
- NCT04404595
- Locations
- 🇺🇸
Karmanos Cancer Center, Detroit, Michigan, United States
🇺🇸University of Southern California, Los Angeles, California, United States
🇺🇸UCSD, San Diego, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath